Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas

Targeted Oncology

Volumn 8, Issue 4, 2013, Pages 261-269

  El Sayadi, Hiba ^a   Pissaloux, Daniel ^a   Alberti, Laurent ^a   Tabone Eglinger, Severine ^a   Ranchere, Dominique ^a   Decouvelaere, Anne Valérie ^a   Tabone, Eric ^a   Ray Coquard, Isabelle ^a   Caux, Christophe ^a   Fayette, Jérome ^a   Blay, Jean Yves ^a,b  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

FAK; Gas6; Leiomyosarcomas; Sarcoma; Targeted therapy; Tyro3; Tyrosine kinase

Indexed keywords

AXL PROTEIN; CASPASE 3; CASPASE 7; FORETINIB; GROWTH ARREST SPECIFIC PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN KINASE C THETA; PROTEIN MSH2; SMALL INTERFERING RNA; TYRO3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; AXL GENE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEIOMYOSARCOMA; MALE; MIDDLE AGED; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SMOOTH MUSCLE; TYRO3 GENE; UPREGULATION; UTERUS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEIOMYOSARCOMA; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PHOSPHORYLATION; PROTEOMICS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; TRANSFECTION; UTERINE NEOPLASMS;

EID: 84890553863     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0249-2     Document Type: Article

References (34)

1. WHO (2002) World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. IARC, Lyon
2. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701-711
3. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CDM, Devesa SS (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer 119:2922-2930
4. Lurkin A, Ducimetière F, Vince DR, Decouvelaere AV, Cellier D, Gilly FN, Salameire D, Biron P, de Laroche G, Blay JY, Ray-Coquard I (2010) Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer 10:150
5. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY, ESMO Guidelines Working Group (2009) Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):132-136
6. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 23:576-584
7. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 25:2755-2763
8. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 27:3126-3132
9. Blay JY, Le Cesne A, Alberti L, Ray-Coquart I (2005) Targeted cancer therapies. Bull Cancer 92(2):E13-E18
10. Helman LJ, Meltzer P (2003) Mechanisms of sarcoma development. Nat Rev Cancer 3:685-694
11. Larramendy ML, Kaur S, Svarvar C, Böhling T, Knuutila S (2006) Gene copy number profiling of soft-tissue leiomyosarcomas by array-comparative genomic hybridization. Cancer Genet Cytogenet 169:94-101
12. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namløs HM, Wang J, Kristiansen BE, Myklebost O (2006) Array comparative genomic hybridization reveals distinct DNA copy number differences between gastro-intestinal stromal tumours and leiomyosarcomas. Cancer Res 66:8984-8993
13. Larramendy ML, Gentile M, Soloneski S, Knuutila S, Böhling T (2008) Does comparative genomic hybridization reveal distinct differences in DNA copy number sequence patterns between leiomyosarcoma and malignant fibrous histiocytoma? Cancer Genet Cytogenet 187:1-11
14. Carneiro A, Francis P, Bendahl PO, Fernebro J, Akerman M, Fletcher C, Rydholm A, Borg A, Nilbert M (2009) Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Investig 89:668-675
15. Pérot G, Derré J, Coindre JM, Tirode F, Lucchesi C, Mariani O, Gibault L, Guillou L, Terrier P, Aurias A (2009) Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 69:2269-2278
16. Linger RM, Keating AK, Earp HS, Graham DK (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100:35-83
17. Nilbert M, Therkildsen C, Nissen A, Akerman M, Bernstein I (2009) Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Fam Cancer 8:209-213
18. Kang GH, Kim KM, Park CK, Kang DY (2009) PKC-theta expression in Ewing sarcoma/primitive neuroectodermal tumour and malignant peripheral nerve sheath tumour. Histopathology 55:368-369
19. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, García- García J, Miquel R, Marco V, Sierra M, Losa R, Lacave A, Braña A, Balbín M, Freije JM (2004) Protein kinase C theta is highly expressed in gastrointestinal stromal tumours but not in other mesenchymal neoplasias. Clin Cancer Res 10:4089-4095
20. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, Dahlbäck B (2009) Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumour advancement and survival. Clin Cancer Res 15:4742-4749
21. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A (2009) The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8:618-626
22. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE (2008) Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268(2):314-324
23. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A (2008) AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68:1905-1915
24. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, Kostron H, Stockhammer G, Ullrich A (2008) Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14:130-138
25. Fernebro J, Francis P, Edén P, Borg A, Panagopoulos I, Mertens F, Vallon-Christersson J, Akerman M, Rydholm A, Bauer HC, Mandahl N, Nilbert M (2006) Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118:1165-1172
26. Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, Walker J, Sun F, Orth A, Schultz PG, Wu X (2009) A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106:17025-17030, Epub 2009 Sep 23
27. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P (2010) Malignant cells fuel tumour growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 115:2264-2273
28. Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM (2011) Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 71:1792-1804
29. Lan Z, Wu H, Li W, Wu S, Lu L, Xu M, Dai W (2000) Transforming activity of receptor tyrosine kinase Tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood 95:633-638
30. Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Théou-Anton N, Lemoine A, Blay JY, Emile JF (2008) KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumours. Clin Cancer Res 14:2285-2294
31. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY (2004) IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 20(111):653-661
32. Cheng Z, Sundberg-Smith LJ, Mangiante LE, Sayers RL, Hakim ZS, Musunuri S, Maguire CT, Majesky MW, Zhou Z, Mack CP, Taylor JM (2011) Focal adhesion kinase regulates smooth muscle cell recruitment to the developing vasculature. Arterioscler Thromb Vasc Biol 31:2193-2202
33. Fridell YW, Villa J Jr, Attar EC, Liu ET (1998) GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 273:7123-7126
34. Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG, Haendeler J, Berk BC (2004) Gas6 inhibits apoptosis in vascular smooth muscle: Role of Axl kinase and Akt. J Mol Cell Cardiol 37:881-887